Trial reportJCI insight2018
First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis.
Trial report in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 156 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis
An Open-Label, Multicenter Study to Evaluate Continued Safety of FB-401 for up to 48 Weeks in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in FB401-01 Phase 2 Study
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis
Who cites it
156 citing papers in PubMed, 306 citations in OpenAlex.
- Commensal Cutibacterium acnes-derived indolelactic acid safeguards skin barrier function through the aryl hydrocarbon receptor.Cell reports. Medicine · 2026Trial
- Topical probioticFrontiers in medicine · 2026Trial
- Microbiological and clinical effects of probiotic-related Zeger therapy on gingival health: a randomized controlled clinical trial.BMC oral health · 2024Trial
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.Dermatology (Basel, Switzerland) · 2024Trial
- Therapeutic responses toScience translational medicine · 2020Trial
- The Effect of Lipopolysaccharide-containing Moisturizing Cream on Skin Care in Patients With Mild Atopic Dermatitis.In vivo (Athens, Greece)Trial
- Skin Microbiome in Health and Disease: Dysbiosis and the Emerging Role of Biotics in Therapy and Protection.International journal of molecular sciences · 2026Review
- Review
- Global Probiotic Markets Meet Synthetic Biology: Translational Challenges andMicroorganisms · 2026Review
- A pilot study investigating the bacterial and fungal community shifts in facial skin in rosacea.The Journal of international medical research · 2026Observational
- Microbial Dysbiosis in Photodermatoses: Formation, Pathogenesis and Intervention Strategies.Current issues in molecular biology · 2026Review
- Skin Microbiota Diversity Is Associated with Biophysical Properties Across Healthy Human Skin Types.Microorganisms · 2026Article
- Human and Marine Host Defense Peptides for Healthy Skin.Marine drugs · 2026Review
- Regulation of allergies across the body by microbial metabolites.Experimental & molecular medicine · 2026Review
- Microbiota Transplantation as a Future Novel Therapeutic Strategy Approach.Diseases (Basel, Switzerland) · 2026Review
- Ex vivo Evaluation of Live-MB2 and CX-2 Biotic Strains on Inflammatory and Barrier-Related Biomarkers in a Human Skin Atopic Dermatitis-Like Model.Clinical, cosmetic and investigational dermatology · 2026Article
- The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Review
- Dynamic remodeling of skin microbiota during healthy homeostatic and wound repair conditions.Frontiers in microbiology · 2026Review
- Microbiome dysbiosis and therapeutic restoration in atopic dermatitis.Frontiers in cellular and infection microbiology · 2026Review
- The microbial peace-signal hypothesis: distributed immune "peace hubs" across the human body.Frontiers in immunology · 2026Review
96 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
The underlying pathology of atopic dermatitis (AD) includes impaired skin barrier function, susceptibility to Staphylococcus aureus skin infection, immune dysregulation, and cutaneous dysbiosis. Our recent investigation into the potential role of Gram-negative skin bacteria in AD revealed that isolates of one particular commensal, Roseomonas mucosa, collected from healthy volunteers (HVs) improved outcomes in mouse and cell culture models of AD. In contrast, isolates of R. mucosa from patients with AD worsened outcomes in these models. These preclinical results suggested that interventions targeting the microbiome could provide therapeutic benefit for patients with AD. As a first test of this hypothesis in humans, 10 adult and 5 pediatric patients were enrolled in an open-label phase I/II safety and activity trial (the Beginning Assessment of Cutaneous Treatment Efficacy for Roseomonas in Atopic Dermatitis trial; BACTERiAD I/II). Treatment with R. mucosa was associated with significant decreases in measures of disease severity, topical steroid requirement, and S. aureus burden. There were no adverse events or treatment complications. We additionally evaluated differentiating bacterial metabolites and topical exposures that may contribute to the skin dysbiosis associated with AD and/or influence future microbiome-based treatments. These early results support continued evaluation of R. mucosa therapy with a placebo-controlled trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.